Claas Wesseler
Overview
Explore the profile of Claas Wesseler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saalfeld F, Moller J, Christopoulos P, Wenzel C, Rasokat A, Wang X, et al.
Eur J Cancer
. 2024 Oct;
213:115065.
PMID: 39423775
Introduction: Small cell transformation (SCT) is a typical mechanism of adaptive resistance to third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the standard of care for EGFR-driven...
2.
Illini O, Saalfeld F, Christopoulos P, Duruisseaux M, Vikstrom A, Peled N, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612799
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed...
3.
Frost N, Wesseler C, Wormann B, Eberhardt W
Pneumologie
. 2024 Apr;
78(4):e1.
PMID: 38608660
No abstract available.
4.
Frost N, Wesseler C, Wormann B, Eberhardt W
Pneumologie
. 2024 Apr;
78(4):233-235.
PMID: 38608657
No abstract available.
5.
Griesinger F, Sebastian M, Brueckl W, Hummel H, Jaeschke B, Kern J, et al.
JTO Clin Res Rep
. 2024 Apr;
5(4):100626.
PMID: 38586301
Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess...
6.
Kim D, Schram A, Hollebecque A, Nishino K, Macarulla T, Rha S, et al.
Future Oncol
. 2024 Feb;
20(16):1057-1067.
PMID: 38348690
Neuregulin 1 () fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. fusions are rare, occurring in less...
7.
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Luders H, et al.
J Thorac Oncol
. 2023 Dec;
19(5):803-817.
PMID: 38096950
Introduction: Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing...
8.
Konermann F, Gessler N, Wohlmuth P, Behr J, Feldhege J, Gloeckner C, et al.
Oncol Res Treat
. 2023 Feb;
46(5):201-210.
PMID: 36822167
Introduction: SARS-CoV-2 infected patients with cancer have a worse outcome including a significant higher mortality, compared to non-cancer patients. However, limited data are available regarding in-hospital mortality during the Omicron...
9.
Kostev K, Gessler N, Wohlmuth P, Arnold D, Bein B, Bohlken J, et al.
J Alzheimers Dis
. 2022 Dec;
91(2):719-726.
PMID: 36463455
Background: Dementia has been identified as a major predictor of mortality associated with COVID-19. Objective: The objective of this study was to investigate the association between dementia and mortality in...
10.
Trummer A, Bethge A, Dickgreber N, Dittrich I, Golpon H, Hoffknecht P, et al.
Lung Cancer
. 2022 Nov;
174:141-145.
PMID: 36402005
Objectives: For refractory NSCLC patients with EGFR mutations, recent studies have demonstrated a favorable response to the combination of anti-angiogenic therapy and checkpoint inhibition but included only very few patients...